HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced it has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor.
The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications, and device hardware.
HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The new patent builds on this foundation, offering potential for monitoring heart failure patients for fluid overload, a common cause of hospitalizations, and detecting structural issues like valvular heart disease earlier.
The integration of acoustic sensing allows the device to capture heart sounds, similar to a stethoscope, which can provide clues about valve function. Thoracic impedance measurement can detect changes in fluid levels in the chest, a key indicator of worsening heart failure. By combining these modalities with the existing 3D ECG capability, HeartBeam aims to create a comprehensive cardiac monitoring tool that could reduce the need for clinic visits and enable proactive management of chronic conditions.
For more details on the full press release, visit https://ibn.fm/jgVf0. Information about HeartBeam’s cleared indications for use is available at https://www.heartbeam.com/indications.
